• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5072826)   Today's Articles (42)
For: Ota Y, Inagaki R, Sumida K, Nakamura M, Nagai Y, Yamamoto S. DSP-0509, a TLR7 agonist, exerted synergistic anti-tumor immunity combined with various immune therapies through modulating diverse immune cells in cancer microenvironment. Front Oncol 2024;14:1410373. [PMID: 39346737 PMCID: PMC11427241 DOI: 10.3389/fonc.2024.1410373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2024] [Accepted: 08/22/2024] [Indexed: 10/01/2024]  Open
Number Cited by Other Article(s)
1
Yim J, Hope C, Huelse JM, Graham DK. Prospects of current AXL-targeting therapies in early phase cancer trials. Expert Opin Investig Drugs 2025:1-33. [PMID: 40413629 DOI: 10.1080/13543784.2025.2511178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2025] [Revised: 04/22/2025] [Accepted: 05/19/2025] [Indexed: 05/27/2025]
2
Matsuda K, Ota Y, Uemachi H, Taoda R, Tsunashima Y, Ban H, Nagai Y. Examination of the potential clinical application of 5DEX-0509R, the tumor macrophage-targeting nanomedicine. Cytokine 2025;186:156842. [PMID: 39721228 DOI: 10.1016/j.cyto.2024.156842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2024] [Revised: 12/02/2024] [Accepted: 12/18/2024] [Indexed: 12/28/2024]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA